Literature DB >> 2587955

The value of C-reactive protein as a marker of bacterial infection in patients with septicaemia/endocarditis and influenza.

S Lindbäck1, U Hellgren, I Julander, L O Hansson.   

Abstract

In order to evaluate the capacity of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell count (WBC) and polymorphonuclear neutrophils (PMNs) to differentiate between bacterial and viral infection we studied 176 patients with septicaemia/endocarditis (SE), 59 patients with uncomplicated influenza (UI) and 22 patients with complicated influenza (CI) retrospectively. All 4 parameters were significantly more elevated in SE and CI than in UI. Among patients with SE 10 176 had a CRP value less than 50 mg/l and in patients with UI 5/56 had a CRP value greater than 100 mg/l. Patients with SE caused by pneumococci had the highest CRP levels and patients with alfa-haemolytic streptococci the lowest. The sensitivity and specificity favours the use of CRP as an indicator of bacterial superinfection in influenza.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2587955     DOI: 10.3109/00365548909037883

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  10 in total

1.  Integration and visualization of host-pathogen data related to infectious diseases.

Authors:  Timothy Driscoll; Joseph L Gabbard; Chunhong Mao; Oral Dalay; Maulik Shukla; Clark C Freifeld; Anne Gatewood Hoen; John S Brownstein; Bruno W Sobral
Journal:  Bioinformatics       Date:  2011-06-27       Impact factor: 6.937

2.  Antibiotic prescribing and C-reactive protein testing for pulmonary infections in patients with intellectual disabilities.

Authors:  Catharina M Peters; Francesca M Schouwenaars; Ellen Haagsma; Heleen M Evenhuis; Michael A Echteld
Journal:  Br J Gen Pract       Date:  2013-05       Impact factor: 5.386

3.  C-reactive protein is more sensitive than erythrocyte sedimentation rate for diagnosis of infective endocarditis.

Authors:  H Hogevik; L Olaison; R Andersson; K Alestig
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

4.  Reliability and feasibility of a near patient test for C-reactive protein in primary care.

Authors:  F D Hobbs; J E Kenkre; Y H Carter; G H Thorpe; R L Holder
Journal:  Br J Gen Pract       Date:  1996-07       Impact factor: 5.386

5.  Control and duration of therapy in complicated UTI--with special consideration of C-reactive protein.

Authors:  D Höffler
Journal:  Infection       Date:  1994       Impact factor: 3.553

6.  C-reactive protein and alpha 1-acid glycoprotein levels in dogs infected with Ehrlichia canis.

Authors:  Y Rikihisa; S Yamamoto; I Kwak; Z Iqbal; G Kociba; J Mott; W Chichanasiriwithaya
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

7.  Serum C-reactive protein and neopterin concentrations in patients with viral or bacterial infection.

Authors:  A C Shaw
Journal:  J Clin Pathol       Date:  1991-07       Impact factor: 3.411

8.  Extension of antimicrobial treatment in patients with left-sided native valve endocarditis based on elevated C-reactive protein values.

Authors:  D W M Verhagen; J Hermanides; J C Korevaar; P M M Bossuyt; R B A van den Brink; P Speelman; J T M van der Meer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-08       Impact factor: 3.267

9.  Combination of procalcitonin and C-reactive protein levels in the early diagnosis of bacterial co-infections in children with H1N1 influenza.

Authors:  Zhihao Li; Liya He; Shuhua Li; Waner He; Caihui Zha; Wanxing Ou; Qiaozhen Hou; Weiying Wang; Xin Sun; Huiying Liang
Journal:  Influenza Other Respir Viruses       Date:  2018-12-01       Impact factor: 4.380

10.  Utility of the FebriDx point-of-care test for rapid triage and identification of possible coronavirus disease 2019 (COVID-19).

Authors:  Nawazish Karim; Muhammad Zubair Ashraf; Muhammad Naeem; Tahir Anwar; Hnin Aung; Srikumar Mallik; Eleni Avraam; Sidra Kiran; Sareesh Bandapaati; Faisal Khan; Georgios Tsaknis; Raja Reddy
Journal:  Int J Clin Pract       Date:  2020-09-17       Impact factor: 3.149

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.